China NMPA Drug Inspection - Huazhong Pharmaceutical Co., Ltd - Dexamethasone sodium phosphate injection
China NMPA drug inspection for Huazhong Pharmaceutical Co., Ltd published September 26, 2019. Drug: Dexamethasone sodium phosphate injection. On September 26, 2019, the National Medical Products Administration (NMPA) announced findings from drug quality tests, i
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
China NMPA drug inspection for Huazhong Pharmaceutical Co., Ltd published September 26, 2019. Drug: Dexamethasone sodium phosphate injection. On September 26, 2019, the National Medical Products Administration (NMPA) announced findings from drug quality tests, i
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox